Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 670220-93-6
2. Crenolanib Besilate
3. Crenolanib Besylate [usan]
4. Aro-002-26
5. Cp-868,596-26
6. Mc4b01024k
7. Cp-868596-26
8. Crenolanib Besylate (usan)
9. 4-piperidinamine, 1-(2-(5-((3-methyl-3-oxetanyl)methoxy)-1h-benzimidazol-1-yl)-8- Quinolinyl)-, Benzenesulfonate (1:1)
10. Cp868596
11. 1-(2-(5-((3-methyloxetan-3-yl)methoxy)-1h-benzo[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine. Phso3h
12. 4-piperidinamine, 1-(2-(5-((3-methyl-3-oxetanyl)methoxy)-1h-benzimidazol-1-yl)-8-quinolinyl)-, Benzenesulfonate (1:1)
13. 4-piperidinamine,1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1h-benzimidazol-1-yl]-8-quinolinyl]-, Monobenzenesulfonate
14. Cp-868
15. Unii-mc4b01024k
16. Schembl4681285
17. Chembl2146086
18. Bcp24113
19. Crenolanib Besilate [who-dd]
20. Akos032947280
21. Sb16604
22. D10103
23. Q27283841
24. 1-(2-(5-((3-methyloxetan-3-yl)methoxy)-1h-benzimidazol-1-yl)quinolin-8-yl)piperidin-4- Amine Monobenzenesulfonate
25. 1-(2-(5-((3-methyloxetan-3-yl)methoxy)-1h-benzimidazol-1-yl)quinolin-8-yl)piperidin-4-amine Monobenzenesulfonate
26. 1-(2-(5-((3-methyloxetan-3-yl)methoxy)-1h-benzo[d]imidazol-1-yl)quinolin-8-yl)piperidin-4-amine Benzenesulfonate
27. 1-{2-[5-(3-methyl-oxetan-3-ylmethoxy)-benzoimidazol-1-yl]-quinolin-8-yl}-piperidin-4-ylamine Benzenesulfonate
28. Benzenesulfonic Acid;1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine
| Molecular Weight | 601.7 g/mol |
|---|---|
| Molecular Formula | C32H35N5O5S |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 6 |
| Exact Mass | 601.23589041 g/mol |
| Monoisotopic Mass | 601.23589041 g/mol |
| Topological Polar Surface Area | 141 Ų |
| Heavy Atom Count | 43 |
| Formal Charge | 0 |
| Complexity | 851 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Digital Content 
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Crenolanib Besylate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Crenolanib Besylate, including repackagers and relabelers. The FDA regulates Crenolanib Besylate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Crenolanib Besylate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Crenolanib Besylate supplier is an individual or a company that provides Crenolanib Besylate active pharmaceutical ingredient (API) or Crenolanib Besylate finished formulations upon request. The Crenolanib Besylate suppliers may include Crenolanib Besylate API manufacturers, exporters, distributors and traders.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Crenolanib Besylate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Crenolanib Besylate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Crenolanib Besylate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Crenolanib Besylate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Crenolanib Besylate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Crenolanib Besylate suppliers with NDC on PharmaCompass.
Crenolanib Besylate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Crenolanib Besylate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Crenolanib Besylate GMP manufacturer or Crenolanib Besylate GMP API supplier for your needs.
A Crenolanib Besylate CoA (Certificate of Analysis) is a formal document that attests to Crenolanib Besylate's compliance with Crenolanib Besylate specifications and serves as a tool for batch-level quality control.
Crenolanib Besylate CoA mostly includes findings from lab analyses of a specific batch. For each Crenolanib Besylate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Crenolanib Besylate may be tested according to a variety of international standards, such as European Pharmacopoeia (Crenolanib Besylate EP), Crenolanib Besylate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Crenolanib Besylate USP).
LOOKING FOR A SUPPLIER?
